Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Replenine-VF in children with severe haemophilia B
NCT02263469Phase 3Completed
- Sponsor
- Bio Products Laboratory
- Start
- Aug 2005
- Primary completion
- Jul 2006
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 3, open-label, single-arm trial of coagulation factor IX human in Hemophilia B (HB), sponsored by Bio Products Laboratory. Primary endpoint: Amount of Factor IX Administered per Month at 26 weeks. Started Aug 2005; status: completed.
02
Drugs
coagulation factor IX human
03
Conditions
Hemophilia B (HB)
Beyond the preview
Go deeper on NCT02263469.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02263469.